Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) reported Q3 2017 earnings this Afternoon, coming in at ($0.44) per share, beating Wall Street’s estimates of ($0.48) per Share. Revenue for the quarter came in at $7.51 million missing the streets estimates of $8.08 million
Analyst Coverage For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
These are 3 Buy Ratings .
The current consensus rating for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is Buy (Score: 3.00) with a consensus target price of $31.00 , a potential (19.48% downside)Recent Insider Trading for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- On 1/4/2017 Yat Sun Or, Insider, sold 13,921 with an average share price of $35.09 per share and the total transaction amounting to $488,487.89.
- On 11/29/2016 Yat Sun Or, Insider, sold 13,921 with an average share price of $31.44 per share and the total transaction amounting to $437,676.24.
- On 5/11/2016 Nathaniel S Gardiner, VP, bought 500 with an average share price of $24.45 per share and the total transaction amounting to $12,225.00.
- On 2/12/2016 Terry Vance, Director, bought 2,000 with an average share price of $27.04 per share and the total transaction amounting to $54,080.00.
- On 11/24/2015 Paul J. Mellett, CFO, sold 6,000 with an average share price of $30.15 per share and the total transaction amounting to $180,900.00.
- On 10/15/2015 Paul J Mellett, CFO, sold 7,500 with an average share price of $40.10 per share and the total transaction amounting to $300,750.00.
Recent Trading for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares of Enanta Pharmaceuticals, Inc. closed the previous trading session at 38.50 up +0.11 0.29% with 144,473 shares trading hands.